[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Baratti D, Kusamura S, Sironi A, Cabras A, Fumagalli L, Laterza B, Deraco M: Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). In Vivo; 2008 Jan-Feb;22(1):153-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
  • BACKGROUND: Multicystic peritoneal mesothelioma (MPM) is an extremely uncommon lesion with uncertain malignant potential.
  • Here, we review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of MPM.
  • Three patients had recurrent disease after 1, 2 and 4 previous debulkings, respectively.
  • MPM recurred in two patients: one is presently disease-free after a second cytoreduction with HIPEC and the other is alive with minimal stable disease.
  • CONCLUSION: Definitive eradication by means of cytoreduction and HIPEC seems a safe and effective therapeutic option for MPM.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mesothelioma, Cystic / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual / pathology. Neoplasm, Residual / therapy. Reoperation. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396799.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Antman K, Hassan R, Eisner M, Ries LA, Edwards BK: Update on malignant mesothelioma. Oncology (Williston Park); 2005 Sep;19(10):1301-9; discussion 1309-10, 1313-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on malignant mesothelioma.
  • Mesotheliomas are uncommon in the United States, with an incidence of about 3,000 new cases per year (or a risk of about 11 per million Americans per year).
  • About 85% of mesotheliomas arise in the pleura, about 91% in the peritoneum, and a small percentage in the pericardium or tunica vaginalis testis.
  • The histology of about half of mesotheliomas is epithelial (tubular papillary), with the remainder sarcomatous or mixed.
  • Multicystic mesotheliomas and well-differentiated papillary mesotheliomas are associated with long survival in the absence of treatment and should be excluded from clinical trials intended for the usual rapidly lethal histologic variants of the disease.
  • Recent randomized trials have shown significant improvement in time to progression and survival for the addition of new antifolates to platinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / diagnosis. Mesothelioma / epidemiology. Mesothelioma / pathology. Mesothelioma / therapy
  • [MeSH-minor] Asbestos / adverse effects. Folic Acid Antagonists / administration & dosage. Folic Acid Antagonists / therapeutic use. Heart Neoplasms / pathology. Humans. Incidence. Male. Neoplasm Staging. Peritoneal Neoplasms / pathology. Platinum Compounds / administration & dosage. Platinum Compounds / therapeutic use. Pleural Neoplasms / pathology. Prognosis. Quality of Life / psychology. Survival Analysis. Testicular Neoplasms / pathology. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285225.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; 0 / Platinum Compounds; 1332-21-4 / Asbestos
  •  go-up   go-down


3. Patel NP, Taylor CA, Levine EA, Trupiano JK, Geisinger KR: Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol; 2007 Sep;128(3):414-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings.
  • Primary peritoneal mesotheliomas (PPMs) are rare tumors of adults.
  • At our institution, PPMs are treated with a combination of cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IPHC) in appropriate patients.
  • Of the corresponding 49 PPM histologic specimens, 46 were epithelial, 2 sarcomatoid, and 1 multicystic mesothelioma.
  • This includes our experience with washing specimens obtained from patients with PPM following treatment with cytoreductive surgery combined with IPHC.
  • [MeSH-major] Ascitic Fluid / pathology. Mesothelioma / pathology. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709315.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M: Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol; 2007 Oct;14(10):2790-7
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
  • BACKGROUND: Multicystic peritoneal mesothelioma (MPM) and well-differentiated papillary peritoneal mesothelioma (WDPPM) are exceedingly uncommon lesions with uncertain malignant potential and no uniform treatment strategy.
  • The aim of the current study was to review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in these clinical settings.
  • Seven patients had recurrent disease after previous debulking (one operation in five patients, two in one, four in one).
  • One patient underwent the procedure twice due to locoregional MPM recurrence.
  • Transition of typical WDPPM to malignant biphasic mesothelioma was documented in one patient who died of disease progression following incomplete cytoreduction and HIPEC.
  • Following multimodality treatment, 5-year overall and progression-free survival were 90.0% (standard error = 9.0) and 79.7% (11.9), respectively.
  • Definitive tumor eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease recurrence or transition to aggressive malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mesothelioma, Cystic / drug therapy. Mesothelioma, Cystic / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Infusions, Parenteral. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / drug therapy. Neoplasm, Residual / mortality. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Reoperation

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17661150.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Passot G, Cotte E, Brigand C, Beaujard AC, Isaac S, Gilly FN, Glehen O: [Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy]. J Chir (Paris); 2008 Sep-Oct;145(5):447-53
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy].
  • [Transliterated title] Mésothéliome péritonéal: traitement par l'association chirurgie de cytoréduction et chimiothérapie hyperthermique intrapéritonéale.
  • Diffuse malignant peritoneal mesothelioma is a rare and lethal disease.
  • Locoregional treatments combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) seem to improve prognosis.
  • RESULTS: Nineteen patients with diffuse malignant peritoneal mesothelioma were included (16 epithelial, 3 biphasic and 3 multicystic forms).
  • Sixteen patients presented stage 3 or 4 peritoneal mesothelioma according to the Gilly classification.
  • CONCLUSION: Cytoreductive surgery combined with HIPEC may improve the length of survival for patients with diffuse malignant peritoneal mesothelioma; such patients should be treated in specialized centers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mesothelioma / drug therapy. Mesothelioma / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106865.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Deraco M, Casali P, Inglese MG, Baratti D, Pennacchioli E, Bertulli R, Kusamura S: Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol; 2003 Jul;83(3):147-53
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.
  • BACKGROUND AND OBJECTIVES: Peritoneal mesothelioma (PM) is a rare disease, with a poor prognosis.
  • We decided to prospectively evaluate the prognostic impact of aggressive surgery followed by intraperitoneal chemotherapy with local hyperthermia.
  • Fifteen (68%) patients had malignant disease, two had well-differentiated papillary mesothelioma, and two had multicystic PM.
  • Thirteen (65%) patients received preoperative chemotherapy.
  • Fifteen cases (75%) underwent optimal cytoreduction (residual disease <2.5 mm).
  • One patient underwent the procedure twice due to locoregional progression.
  • CONCLUSIONS: This therapeutic strategy proved feasible and was well tolerated.
  • Early results seem promising and consistent with a potentially major impact on survival in selected patients with PM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced / methods. Mesothelioma / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Drug Administration Routes. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Prospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12827682.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Mutafoğlu-Uysal K, Kargi A, Sarialioğlu F, Olgun N, Kovanlikaya A: Malignant pleural mesothelioma in a child: long-term survival with ICE-WAC chemotherapy regimen. Turk J Pediatr; 2002 Jul-Sep;44(3):244-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma in a child: long-term survival with ICE-WAC chemotherapy regimen.
  • Malignant mesothelioma is a very rare tumor in childhood.
  • Presently, treatment of this disease continues to be frustrating and prognosis remains poor.
  • We here report a pediatric case of malignant pleural mesothelioma who gave a complete response to ICE-VAC chemotherapy regimen and achieved a long-term survival.
  • An eight-year-old girl underwent exploratory thoracotomy and decortication because of a unilateral loculated and multicystic pleural effusion.
  • Histopathological diagnosis was sarcomatoid pleural malignant mesothelioma.
  • After decortication, chemotherapy with ICE (ifosfamide, carboplatin, etoposide) - VAC (vincristine, adriamycin, cyclophosphamide) combination was started.
  • Six courses of chemotherapy resulted in complete clinical and radiological tumor response.
  • She did not receive any further therapy and remains disease-free three years after the first remission.
  • ICE-VAC chemotherapy combination resulted in a complete tumor response and a long-term disease-free survival for the presented case.
  • The efficacy of this chemotherapy regimen in malignant mesothelioma needs to be documented in future trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Etoposide / therapeutic use. Ifosfamide / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Child. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12405438.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 3; VAC protocol
  •  go-up   go-down


8. Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O: Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol; 2006 Mar;13(3):405-12
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
  • BACKGROUND: Peritoneal mesothelioma is a rare disease with few therapeutic options.
  • Recently, the combination of cytoreductive surgery with intraperitoneal hyperthermic chemotherapy (HIPEC) has shown promising results.
  • METHODS: Fifteen patients with peritoneal mesothelioma who were treated by cytoreductive surgery and HIPEC between 1989 and 2004 were identified from a prospective database.
  • RESULTS: All patients but one (multicystic) had malignant disease of the following pathologic types: 12 epithelial and 2 biphasic.
  • The overall median survival for the 14 patients with malignant mesothelioma was 35.6 months.
  • The median survival was 37.8 months for patients treated with a CC-0 or CC-1 resection, whereas it was 6.5 months for those treated with a CC-2 or CC-3 resection (diameter of residual nodules >2.5 mm; P < .001).
  • CONCLUSIONS: A therapeutic strategy combining cytoreductive surgery with HIPEC seems to provide an adequate and efficient locoregional treatment for peritoneal mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced. Mesothelioma / drug therapy. Mesothelioma / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Intraoperative Period. Male. Middle Aged. Mitomycin / administration & dosage. Prospective Studies. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485159.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Baratti D, Vaira M, Kusamura S, D'Amico S, Balestra MR, Cioppa T, Mingrone E, De Simone M, Deraco M: Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Eur J Surg Oncol; 2010 Nov;36(11):1047-53
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
  • AIM: This retrospective multi-institutional study addresses the role of surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of multicystic peritoneal mesothelioma (MCPM).
  • MCPM is an uncommon tumour with uncertain malignant potential and no current standard therapy.
  • Additionally, poorly defined pathological and biological features of this disease were investigated.
  • Nine patients had recurrent disease after previous debulking (one operation in six patients, two in two, four in one).
  • Biological markers related to mesothelioma origin and clinical features were assessed by immunohistochemical studies.
  • All the patients are presently alive with no evidence of disease, including two patients who underwent the procedure twice, due to locoregional disease recurrence.
  • CONCLUSIONS: MCPM is a borderline tumour with a high propensity to local-regional recurrence.
  • Definitive tumour eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Mesothelioma / pathology. Mesothelioma / therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Female. Humans. Infusions, Parenteral. Kaplan-Meier Estimate. Length of Stay. Male. Middle Aged. Neoplasm, Residual / pathology. Patient Selection. Prognosis. Retrospective Studies. Surgical Procedures, Operative / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20832234.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Milano E, Pourroy B, Rome A, Delarue A, Coze C, Gorincour G, Bouvier C, Braguer D, André N: Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma. Anticancer Drugs; 2006 Nov;17(10):1231-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma.
  • We report the case of an 11-year-old girl with a recurrent progressive locally advanced abdominal mesothelioma.
  • First, there was an incomplete surgical resection without any complementary chemotherapy, followed by a slow progression of the disease.
  • Three years later, after two macroscopically complete surgical resections of peritoneal and ovarian tumors, she failed to respond to treatment with gemcitabin-carboplatin and gemcitabin-cisplatin, and developed splenic tumors and large multicystic hepatic tumors.
  • The schedule of chemotherapy was pemetrexed 400 mg intravenously plus cisplatin 60 mg once every 3 weeks associated with folic acid and vitamin B12.
  • The tumor reduction was evaluated with positron emission tomography scan and tomodensitometry every three courses.
  • Chemotherapy tolerance was good apart from a grade III neutropenia at the second course, a fever of unknown origin at the fifth course and a grade III thrombocytopenia at the sixth course.
  • Fourteen months after the surgery, the girl remained in partial remission with stable disease.
  • So far, pemetrexed associated with cisplatin revealed a good tolerance and promising results regarding its antitumoral efficacy in a progressive metastatic abdominal mesothelioma in childhood.
  • [MeSH-major] Glutamates / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Mesothelioma / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / radiography. Abdominal Neoplasms / secondary. Abdominal Neoplasms / surgery. Antimetabolites, Antineoplastic / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Pemetrexed. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075325.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


11. Charfi S, Chetaille B, Marcy M, Turrini O, Chaise De Maison C, Delpero JR, Viret F, Xerri L, Monges G: Multicystic peritoneal mesothelioma: report of three cases. Pathologica; 2008 Oct;100(5):416-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicystic peritoneal mesothelioma: report of three cases.
  • Multicystic peritoneal mesothelioma is a rare lesion occurring mainly in women in a reproductive age.
  • We report three cases of multicystic peritoneal mesothelioma in patients that were 28, 38 and 47 years of age (one male, two females).
  • Explorative laparotomy was presumptive of a pseudomyxoma peritoni in two cases, and hyperthermic intraperitoneal chemotherapy was performed.
  • Histological examination demonstrated multicystic lesions with mesothelial cells lining confirmed by immunohistochemical analysis.
  • The clinical presentation, pathogenesis and pathologic features including differential diagnosis of multicystic peritoneal mesothelioma are discussed.
  • [MeSH-major] Mesothelioma, Cystic / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendectomy. Combined Modality Therapy. Dermoid Cyst. Diagnosis, Differential. Endometriosis / complications. Female. Humans. Hyperthermia, Induced. Intestinal Perforation / etiology. Laparotomy. Male. Middle Aged. Neoplasms, Multiple Primary. Ovarian Neoplasms. Peritonitis / etiology. Pseudomyxoma Peritonei / diagnosis. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253604.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Szöllósi A, Ferenc C, Pintér T, Erényi A, Nagy A: [Benign cystic mesothelioma, a rare tumor of the peritoneum]. Magy Seb; 2005 Feb;58(1):35-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign cystic mesothelioma, a rare tumor of the peritoneum].
  • [Transliterated title] Benignus cisztikus mesothelioma, a peritoneum ritka daganata.
  • Appendicetomy was performed, during the operation multiple cystic lesions were discovered on the right ovary and the peritoneal surface of the mesentery.
  • Laparatomy was performed with removal of the visible cystic lesions, which contained mucous fluid.
  • Final histology revealed benign cystic mesothelioma, which is a rare lesion of the peritoneum, occurring mainly in women in reproductive age.
  • The etiology of cystic mesothelioma is still unclear.
  • Some authors reported effective intraperitoneal chemotherapy, but no clinical study is available about long term outcome.
  • [MeSH-major] Mesothelioma, Cystic. Peritoneal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16018599.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down






Advertisement